OBJECTIVE: Our objective was to establish the clinical, genetic, metabolic, and immunologic risk factors for the progression of the albumin excretion rate (AER) in normoalbuminuric NIDDM patients. RESEARCH DESIGN AND METHODS: We recruited 108 NIDDM patients with normal AER after a diabetes duration of 9 years to participate in a prospective 9-year follow-up. In addition to conventional clinical and metabolic variables, we assessed microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary heart disease, peripheral vascular disease) diabetic complications, genetic markers (HLA genotypes), and organ-specific autoimmune markers, including islet cell antibodies. Multiple logistic regression was used to determine independent predictors of progression of AER. RESULTS: A total of 21 patients (19%) died during the follow-up. There was an overrepresentation of men (61 vs. 39%; P = 0.044) and smokers (55 vs. 27%; P = 0.01) in patients who progressed to micro- or macroalbuminuria versus those who did not progress. In addition, progressors had higher fasting plasma glucose (P = 0.002) and HbA1 (P = 0.0002) concentrations at baseline than did nonprogressors. Neuropathy was more often seen in progressors than in nonprogressors at baseline (53 vs. 16%; P = 0.0004). Frequency of HLA genotypes and autoimmune markers did not differ between progressors and nonprogressors. In a multiple logistic regression analysis, HbA1 (P = 0.0005) and a history of smoking (P = 0.011) were independent predictors of progression of AER. CONCLUSIONS: This study reemphasizes the importance of poor glycemic control and smoking as independent risk factors for progression of AER. Furthermore, development of micro- or macroalbuminuria in NIDDM was associated with neuropathy and male sex.
OBJECTIVE: Our objective was to establish the clinical, genetic, metabolic, and immunologic risk factors for the progression of the albumin excretion rate (AER) in normoalbuminuric NIDDMpatients. RESEARCH DESIGN AND METHODS: We recruited 108 NIDDMpatients with normal AER after a diabetes duration of 9 years to participate in a prospective 9-year follow-up. In addition to conventional clinical and metabolic variables, we assessed microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary heart disease, peripheral vascular disease) diabetic complications, genetic markers (HLA genotypes), and organ-specific autoimmune markers, including islet cell antibodies. Multiple logistic regression was used to determine independent predictors of progression of AER. RESULTS: A total of 21 patients (19%) died during the follow-up. There was an overrepresentation of men (61 vs. 39%; P = 0.044) and smokers (55 vs. 27%; P = 0.01) in patients who progressed to micro- or macroalbuminuria versus those who did not progress. In addition, progressors had higher fasting plasma glucose (P = 0.002) and HbA1 (P = 0.0002) concentrations at baseline than did nonprogressors. Neuropathy was more often seen in progressors than in nonprogressors at baseline (53 vs. 16%; P = 0.0004). Frequency of HLA genotypes and autoimmune markers did not differ between progressors and nonprogressors. In a multiple logistic regression analysis, HbA1 (P = 0.0005) and a history of smoking (P = 0.011) were independent predictors of progression of AER. CONCLUSIONS: This study reemphasizes the importance of poor glycemic control and smoking as independent risk factors for progression of AER. Furthermore, development of micro- or macroalbuminuria in NIDDM was associated with neuropathy and male sex.
Authors: Jiaqiong Xu; Elisa T Lee; Richard B Devereux; Jason G Umans; Jonathan N Bella; Nawar M Shara; Jeunliang Yeh; Richard R Fabsitz; Barbara V Howard Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: S S Roscioni; D de Zeeuw; M E Hellemons; H Mischak; P Zürbig; S J L Bakker; R T Gansevoort; H Reinhard; F Persson; M Lajer; P Rossing; H J Lambers Heerspink Journal: Diabetologia Date: 2012-10-20 Impact factor: 10.122
Authors: Merel E Hellemons; Magdalena Mazagova; Ron T Gansevoort; Robert H Henning; Dick de Zeeuw; Stephan J L Bakker; Hiddo J Lambers-Heerspink; Leo E Deelman Journal: Diabetes Care Date: 2012-07-18 Impact factor: 19.112
Authors: Jung-Im Shin; Alex R Chang; Morgan E Grams; Josef Coresh; Shoshana H Ballew; Aditya Surapaneni; Kunihiro Matsushita; Henk J G Bilo; Juan J Carrero; Gabriel Chodick; Kenn B Daratha; Simerjot K Jassal; Girish N Nadkarni; Robert G Nelson; Christoph Nowak; Nikita Stempniewicz; Keiichi Sumida; Jamie P Traynor; Mark Woodward; Yingying Sang; Ron T Gansevoort Journal: Hypertension Date: 2021-08-09 Impact factor: 9.897